Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide OLE in MC4R Pathway Diseases
NCT06596135Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in obesity, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Safety and tolerability of setmelanotide assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 3 years. Started Oct 2024; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06596135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596135.